The company also has filed with the FDA the final report from its Phase III equivalent studies of the drug for that indication. * Genentech Inc., of South San Francisco, began Phase I trials of thrombopoietin for thrombocytopenia, or reduction in platelets, in cancer patients undergoing chemotherapy. * MedImmune Inc., of Gaithersburg, Md., licensed exclusive worldwide rights to human papillomavirus vaccine technology developed at the University of Rochester, in New York. * Receptagen Ltd., of

Celsior is a solution containing antioxidants, nutrients and buffering agents. * Texas Biotechnology Corp., of Houston, is extending its agreement with South San Francisco-based Genentech Inc

The nuclear matrix target that will be used in screening is called nuclear mitotic apparatus protein. * NeXstar Pharmaceuticals Inc., of Boulder, Colo., said it filed regulatory dossiers in 11 European countries seeking approval of DaunoXome as a primary treatment for advanced HIV-associated Kaposi's sarcoma. * Texas Biotechnology Corp., of Houston, is extending its agreement with South San Francisco-based Genentech Inc

Athena Neurosciences Inc., of South San Francisco, said preliminary results of a second pivotal trial of Diastat, or diazepam, showed the drug achieved a statistically significant effect in reducing the number of recurrent seizures in epileptics suffering from a condition called acute repetitive seizure

Lead investors were Allen and Co., of New York, and New Enterprise Associates, of San Francisco

The funds were awarded through the NIH's Strategic Programs for Innovative Research on Aids Treatment. * Genentech Inc., of South San Francisco, completed the purchase of 100 acres in Vacaville, Calif., and launched preliminary work on a more than $150 million first phase for construction of a new manufacturing facility, scheduled to be complete by late 1998. * Geron Corp., of Menlo Park, Calif., received three research grants worth $2.4 million to develop drugs and diagnostics based on

and Pacific Growth Equities, both of San Francisco _ to cover overallotments

Cambridge Antibody Technology, of Cambridge, England, received a $2 million equity investment from Genentech Inc., of South San Francisco, for a non- exclusive license to the U.K.-based company's antibody libraries and associated technologies

OncorMed has exclusive worldwide rights to HCI's hereditary database and added exclusive worldwide commercialization rights to HCI's DNA library. * Paraxel International Corp., a Boston-based contract research organization, opened offices in Milan, Italy, and Kobe, Japan. * Therexsys Ltd., of Staffordshire, England, signed an agreement with Gryphon Sciences, of South San Francisco, to evaluate Gryphon's chemical ligation technologies in Therexsys' targeted gene-delivery system. * Allelix

San Francisco, said there were no dose-limiting adverse effects from a Phase Ib study of APC 366, a tryptase inhibitor for asthma. * Cell Genesys Inc., of Foster City, Calif., and JT Immunotech USA Inc., of San Mateo, Calif., a subsidiary of Tokyo-based Japan Tobacco Inc., to extend for two years their 1991 agreement to develop human antibody-producing mice

Genta has raised gross proceeds of $12.75 million this year. * Shaman Pharmaceuticals Inc., of South San Francisco, obtained from Bayer AG the license for patents relating to the use of a compound called nikkomycin Z for the development of antifungal agents. * Alteon Inc., of Ramsey, N.J., licensed patents from Washington University in St. Louis covering pimagedine, which Alteon is developing as its lead product for treatment of diabetes patients with kidney disease

The company said it has funds to keep operating through early 1996. * Athena Neurosciences Inc., of South San Francisco, and Eli Lilly and Co., of Indianapolis, amended their agreement on development of treatments for Alzheimer's disease to include joint ownership rights to their transgenic mouse model, which is used in studying the disorder

The company received no proceeds. * Genentech Inc., of South San Francisco, and Roche Holdings Inc., of Basel, Switzerland, are changing the form of their agreement made earlier this month because Genentech's stockholders are not expected to vote on the matter until after June 30

IDEC-C2B8, an anti-CD20 monoclonal antibody, is being developed in association with Genentech Inc., of South San Francisco. * Chemex Pharmaceuticals Inc., of Fort Lee, has been removed from NASDAQ because of failure to meet certain financial listing requirements

Blech was forced to shut down his investment firm last fall following a liquidity crisis. * Arris Pharmaceutical Corp., of South San Francisco, received an exclusive license from the University of California at San Francisco to technology for developing protease inhibitors

It differs from other diphtheria, tetanus and pertussis vaccines in that it is not based on whole-cell pertussis, which has been associated with adverse side effects. * AMDL Inc., of Tustin, Calif., closed a private placement of shares and warrants that could bring in total proceeds of $625,000. * Arris Pharmaceuticals Corp., of South San Francisco, started Phase I-B multiple dose tolerance study of APC 366, a tryptase inhibitor for asthma. * Biomatrix Inc., of Ridgefield, N.J., signed a

The Phase I study is being conducted at The University of Texas M.D. Anderson Cancer Center. * Tularik Inc., of South San Francisco, is collaborating with Sumitomo Pharmaceuticals Co

Among the diseases targeted by Ampligen are hepatitis B and cancer. * Athena Neurosciences Inc., of South San Francisco, has acquired Exemplar Corp., of Waltham, Mass., for $100,000 in cash and 420,000 shares of Athena common stock

The treatment is considered a potential substitute for conventional bone marrow or mobilized peripheral blood transplants. * Genentech Inc., of South San Francisco, has filed a federal lawsuit against Bio-Technology General Corp., of Iselin, N.J., and Novo-Nordisk AS, of Denmark, alleging infringement of patents relating to Genentech's recombinant human growth hormone